Regulatory Guidance Monthly Review - August 2019

Contact Veristat Now


Request A Proposal

Contact Us

September 3, 2019

August 2019 Updates from FDA 


Veristat's March 2019 Review of FDA Regulatory Guidances and EMA updatesEach month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in August 2019.

 



FDA Updates


Draft Guidance icon

 

FDA has Finalized the Following Draft Guidance Documents:

 

 

Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry (Published 28Aug2019)

https://www.fda.gov/media/130326/download

 

Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry (14Aug2019)

https://www.fda.gov/media/129899/download

 

Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry (13Aug2019)

https://www.fda.gov/media/129881/download

 

Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry (01Aug2019)

https://www.fda.gov/media/129547/download

 

Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry (31Jul2019)

https://www.fda.gov/media/129530/download

 

Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry (31Jul2019)

https://www.fda.gov/media/129531/download

 

Vulvovaginal Candidiasis: Developing Drugs for Treatment Guidance for Industry (31Jul2019)

https://www.fda.gov/media/129537/download

 

 

 

NewGuidance_icon
FDA has Issued the Following New Draft Guidance Documents:

 

 

Male Breast Cancer: Developing Drugs for Treatment Guidance for Industry (Published 27Aug2019)

https://www.fda.gov/media/130061/download

 

Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry (13Aug2019)

https://www.fda.gov/media/129880/download

 

Fabry Disease: Developing Drugs for Treatment Guidance for Industry (07Aug2019)

https://www.fda.gov/media/129690/download

 

E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES (31Jul2019)

https://www.fda.gov/media/129527/download

 

General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry (31Jul2019)

https://www.fda.gov/media/129532/download

 

Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers Guidance for Industry (31Jul2019)

https://www.fda.gov/media/129533/download

 

FDA News Update Icon

 

 FDA In The News: 

 

 

FDA Probe Into Patient Infections Over Contaminated Duodenoscopes Hits Turning Point (Published 30Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/fda-probe-into-patient-infections-over-contaminate

 

EMA Offers Edits on FDA Draft Guidance on Biosimilars (Published 29Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/ema-offers-edits-on-fda-draft-guidance-on-biosimil

 

WHO Launches Registry for Gene Editing Studies (29Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/who-launches-registry-for-gene-editing-studies

 

EU Regulatory Roundup: AstraZeneca Gets Clearance to Export Calquence API to EU in No-Deal Brexit (Published 29Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/eu-regulatory-roundup-astrazeneca-gets-clearance

 

EC Cites Regulatory Controls for Medical Devices as US-EU Trade Barriers (published 07Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/ec-cites-regulatory-controls-for-medical-devices-a

 

Updated: FDA Reviewing Data Manipulation in Application for Novartis Gene Therapy Zolgensma (Published 06Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/fda-reviewing-data-manipulation-in-application-for

 

eCTD Submission Management (05Aug2019)

https://www.raps.org/news-and-articles/news-articles/2019/8/ectd-submission-management

 

FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making (Published August 2019)

https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical

 

Global public meeting on draft ICH guideline on clinical trials (Published 30Aug2019)

 https://www.ema.europa.eu/en/news/global-public-meeting-draft-ich-guideline-clinical-trials

 

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. FDA Drug Safety Communication (Published 28Aug2019)

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and

 

Just the Stats, Ma’am: FDA Increases Inspections in Foreign Countries, Resulting in a Higher Rate of Enforcement Actions than Imposed on U.S. Facilities (Published 30Aug2019)

http://www.fdalawblog.net/2019/08/just-the-stats-maam-fda-increases-inspections-in-foreign-countries-resulting-in-a-higher-rate-of-enforcement-actions-than-imposed-on-u-s-facilities/

 

Laser-charged gold nanoparticles destroy prostate tumors in first-in-human study (Published 29Aug2019)

https://www.fiercebiotech.com/medtech/laser-charged-gold-nanoparticles-destroy-prostate-tumors-first-human-study

 

EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US (Published 16Aug2019)

https://www.ema.europa.eu/en/news/emafda-analysis-shows-high-degree-alignment-marketing-application-decisions-between-eu-us

 

Supporting medicine developers in generating quality data packages in early access approaches (PRIME and breakthrough therapies): workshop report published (Published 31Jul2019)

https://www.ema.europa.eu/en/news/supporting-medicine-developers-generating-quality-data-packages-early-access-approaches-prime

 

Brexit-related guidance for companies

https://www.ema.europa.eu/en/about-us/uks-withdrawal-eu/brexit-related-guidance-companies

 

 


 

Explore-More-Image-1